CheckSum

CheckSum is an Oxford-based biotechnology company specializing in the development of next-generation DNA damage response (DDR) therapeutics. Spun out from the University of Oxford, the company leverages its proprietary platform to identify and target synthetic lethal vulnerabilities in cancer cells, particularly those with defects in homologous recombination. Its lead program focuses on the development of small molecule inhibitors of DNA polymerase theta (POLQ), an enzyme critical for microhomology-mediated end joining (MMEJ) in repair-deficient tumors. By targeting these specific pathways, CheckSum aims to provide more effective and less toxic treatment options for patients with hard-to-treat malignancies. The company is backed by leading life science investors and maintains strong academic ties to the Oxford oncology research community.